Skip to main content
PeopleBio, Inc. logo

PeopleBio, Inc. — Investor Relations & Filings

Ticker · 304840 ISIN · KR7304840002 KO Manufacturing
Filings indexed 250 across all filing types
Latest filing 2020-11-05 Major Shareholding Noti…
Country KR South Korea
Listing KO 304840

PeopleBio, Inc. is a biotechnology company specializing in the development and manufacturing of diagnostic products for protein misfolding diseases. The company's primary focus is on degenerative brain disorders, particularly Alzheimer's disease. It develops blood-based diagnostic kits and immunoassays designed for early detection. By providing tools for early diagnosis, PeopleBio aims to facilitate timely intervention and treatment, thereby improving patient outcomes for these conditions.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership (specifically a decrease in holdings) by UTC Investment and its related funds in the company PeopleBio. This type of filing is used to notify the market of significant changes in shareholding thresholds, which falls under the 'Major Shareholding Notification' category.
2020-11-05 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and the Korea Exchange. This type of filing is used by institutional investors (in this case, Timefolio Asset Management) to disclose changes in their ownership stake in a specific company (PeopleBio). According to the provided definitions, this corresponds to a 'Major Shareholding Notification'.
2020-11-03 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details the acquisition of shares by '엘에스케이 제1호 사모투자합자회사' in '(주)피플바이오', crossing the 5% threshold. This is a classic 'Major Shareholding Notification' (often referred to as a 5% report).
2020-10-23 Korean
[기재정정]주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Services Commission and the Korea Exchange. This type of filing is used to disclose significant changes in share ownership (crossing the 5% threshold) by an entity and its special relations. In the provided taxonomy, this falls under 'Major Shareholding Notification'.
2020-10-23 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as the 5% rule report). It details the shareholding status of UTC Investment and its related funds in PeopleBio. This falls under the category of Major Shareholding Notification (MRQ) as it tracks changes in significant ownership levels.
2020-10-23 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming Investor Relations (IR) event (Corporate Day). It provides details such as the date, time, location (online), target audience (institutional investors), and the agenda. Since it is an announcement of an event rather than the presentation slides themselves, and it serves as a regulatory notification of corporate activity, it fits best under the 'Regulatory Filings' category as it is a standard disclosure of an IR event schedule.
2020-10-23 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.